| Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed … J Fangusaro, J Finlay, R Sposto, L Ji, M Saly, S Zacharoulis, ... Pediatric blood & cancer 50 (2), 312-318, 2008 | 159 | 2008 |
| Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study SP Ivy, RS Olshefski, BJ Taylor, KM Patel, GH Reaman | 97 | 1996 |
| Glucosylceramide synthase inhibition enhances vincristine‐induced cytotoxicity RS Olshefski, S Ladisch International journal of cancer 93 (1), 131-138, 2001 | 87 | 2001 |
| Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings LA Binkovitz, RS Olshefski, BH Adler Pediatric radiology 33, 598-602, 2003 | 83 | 2003 |
| Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial R Venkatramani, L Ji, J Lasky, K Haley, A Judkins, S Zhou, R Sposto, ... Journal of neuro-oncology 113, 285-291, 2013 | 77 | 2013 |
| Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade RA Altura, RS Olshefski, Y Jiang, DR Boue British journal of cancer 89 (9), 1743-1749, 2003 | 76 | 2003 |
| Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on “Head Start” III: a multi-institutional, prospective clinical trial G Dhall, SH O’Neil, L Ji, K Haley, AM Whitaker, MD Nelson, F Gilles, ... Neuro-oncology 22 (12), 1862-1872, 2020 | 64 | 2020 |
| Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas R Salloum, MK McConechy, LG Mikael, C Fuller, R Drissi, M DeWire, ... Acta neuropathologica communications 5, 1-12, 2017 | 59 | 2017 |
| Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols A Saha, CG Salley, P Saigal, L Rolnitzky, J Goldberg, S Scott, R Olshefski, ... Pediatric blood & cancer 61 (9), 1644-1672, 2014 | 59 | 2014 |
| Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas K Dorris, M Sobo, A Onar-Thomas, E Panditharatna, CB Stevenson, ... Journal of neuro-oncology 117, 67-76, 2014 | 52 | 2014 |
| Intercellular transfer of shed tumor cell gangliosides R Olshefski, S Ladisch FEBS letters 386 (1), 11-14, 1996 | 51 | 1996 |
| Modifying intracellular redox balance: an approach to improving therapeutic index WJM Hrushesky, P Wood, R Olshefski, S Meshnick, JW Eaton The Lancet 325 (8428), 565-567, 1985 | 45 | 1985 |
| Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: abrogation by a new inhibitor of glucosylceramide synthase R Olshefski, S Ladisch Journal of neurochemistry 70 (2), 467-472, 1998 | 43 | 1998 |
| Body issues, sexual satisfaction, and relationship status satisfaction in long‐term childhood cancer survivors and healthy controls V Lehmann, M Hagedoorn, CA Gerhardt, M Fults, RS Olshefski, ... Psycho‐oncology 25 (2), 210-216, 2016 | 42 | 2016 |
| A multi-institutional experience in pediatric high-grade glioma S Walston, DA Hamstra, K Oh, G Woods, M Guiou, RS Olshefski, ... Frontiers in oncology 5, 28, 2015 | 24 | 2015 |
| Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes R Olshefski, B Taylor, A Heitger, A Hasegawa, S Ladisch European journal of biochemistry 241 (1), 47-55, 1996 | 24 | 1996 |
| A quest for meaning: A qualitative exploration among children with advanced cancer and their parents MR Schaefer, AE Kenney, AC Himelhoch, KM Howard Sharp, ... Psycho‐Oncology 30 (4), 546-553, 2021 | 23 | 2021 |
| Trajectories of health behaviors across early childhood cancer survivorship RS Fisher, JR Rausch, AC Ferrante, KV Prussien, RS Olshefski, ... Psycho‐Oncology 28 (1), 68-75, 2019 | 23 | 2019 |
| Comparison of thyroid nodule prevalence by ultrasound in childhood cancer survivors with and without thyroid radiation exposure C Agrawal, L Guthrie, MS Sturm, J Stanek, L Martin, M Henwood-Finley, ... Journal of pediatric hematology/oncology 38 (1), 43-48, 2016 | 21 | 2016 |
| Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL) A Forero-Torres, RB Berryman, RH Advani, NL Bartlett, RW Chen, ... Blood 118 (21), 3711, 2011 | 21 | 2011 |
